TrialPhase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines
Trial details
- Registry ID
- NCT05372588
- Phase
- Phase 3
Drug research
NVX-Cov2373
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as SARS-CoV-2 rS/Matrix-M Adjuvant
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Phase 3 Boosting Study for the SARS-CoV-2 rS Variant VaccinesNCT05372588 | Novavax | Phase 3 | Completed | 2022-07-17Actual |
| Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in AdultsNCT05463068 | Novavax | Phase 3 | Completed | 2022-08-17Actual |
Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults
Trial details
- Registry ID
- NCT05463068
- Phase
- Phase 3
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |